Regeneron scored a genuine first on Wednesday when the FDA approved Livsayis (cemdisiran) for adults with AChR-antibody-positive generalized myasthenia gravis. It is the first and only siRNA therapy cleared in this indication, and the only approved treatment given subcutaneously four times a year. That is a real differentiator in a market where weekly infusions or injections remain the norm. The question for investors is not whether the science is interesting. It is whether Regeneron (REGN) is the right way to own this story, or whether Alnylam Pharmaceuticals (ALNY) is.
The Business
Livsayis works by silencing complement C5, the protein driving the errant immune response behind myasthenia gravis. It was discovered by Alnylam and licensed to Regeneron in 2019 as part of a broad RNAi-focused partnership. In the Phase 3 NIMBLE trial, Livsayis produced a 4.5-point improvement on the MG-ADL daily living score at 24 weeks versus 2.2 points for placebo, a 2.3-point placebo-adjusted gain. That is a meaningful clinical result. Regeneron has not disclosed a U.S. list price in its approval announcement.
Livsayis is Regeneron’s first approved siRNA and first neurology medicine, though the label includes a boxed warning for meningococcal infection and a Risk Evaluation and Mitigation Strategy consistent with other C5 therapies. That safety language matters for launch dynamics. Prescribers and payers have seen it before with rival C5 inhibitors, but it adds friction to onboarding new patients.
Why Wall Street Is Paying Attention
The market’s initial reaction to the approval was underwhelming for REGN. Regeneron shares closed at $923.34 on Thursday, November 19, 2026 as investors weighed the launch opportunity against the broader pipeline. That muted response reflects what the stock already carries: Regeneron reported Q3 2026 revenue of about $5.1 billion and non-GAAP EPS of $20.07. Livsayis enters a Regeneron that is already running hot.
The more interesting number belongs to Alnylam. Per the collaboration agreement, Alnylam receives a $25 million payment on the approval and is eligible for tiered, double-digit royalties of up to 15 percent on global net sales. That is a capital-light royalty, with Regeneron shouldering the commercial execution risk. For ALNY, this is the seventh FDA-approved therapeutic from its RNAi platform, another proof point for a business model that earns on other companies’ wins.
What’s Driving the Opportunity
Livsayis enters a crowded field. The myasthenia gravis market is currently led by argenx and UCB. Argenx’s VYVGART franchise is a formidable incumbent: the company generated $1.7 billion in product net sales in Q3 2026, representing 54 percent year-over-year growth. That is revenue Regeneron will be chipping at from a standing start.
Quarterly dosing is Livsayis’s real pitch, and in a disease where patients are already managing significant burden, four injections per year rather than weekly or biweekly treatments is a clinically meaningful argument. Whether neurologists and payers agree on access and reimbursement at launch remains the central uncertainty.
What Could Go Wrong
Regeneron’s track record on commercial launches is strong, but Livsayis faces headwinds that dosing convenience alone may not solve. Argenx holds label breadth, with VYVGART approved across adult gMG serotypes, and is now pursuing ocular MG as an additional indication. That expanding moat makes gaining share harder, not easier, over time.
For ALNY, the concern is different. Even with the Livsayis approval, sentiment around Alnylam has weakened sharply, with the share price down about 36 percent over the past month and the one-year total return down about 68 percent. A royalty stream worth celebrating does not automatically fix a stock in a sustained downtrend. The royalty dollars are real; whether they are enough to change the technical damage is a separate question.
The Bottom Line
Regeneron is the better business here today. Truist reiterated a Buy with a $982 price target after the approval, and Bank of America reiterated a $1,030 target and Barclays maintained a $1,075 objective, both with buy-equivalent ratings. REGN trades at roughly 20 times trailing earnings with Dupixent still growing and Livsayis adding a new commercial leg in neurology. The valuation is not demanding for the quality on offer.
Alnylam is the cleaner royalty trade on paper, but the chart is broken and the stock demands a higher tolerance for uncertainty. REGN, at current levels, offers a more direct claim on Livsayis upside inside a portfolio that is already outperforming. That combination makes Regeneron the more compelling choice today, with the caveat that this is a launch-stage story and early prescription data will determine whether the dosing advantage translates into durable market share against an argenx franchise that has shown no sign of slowing down.
